Clinical Data Boehringer advances duo for aggressive cancers into phase 3 PharmaphorumBoehringer Ingelheim steps up its push into oncology with phase 3 trials for pathfinder product Hernexeos and obrixtamig in hard-to-treat cancers.OncologyRead full story pharminent June 22, 2026 (Last updated: June 22, 2026) Pharmaphorum Boehringer Ingelheim steps up its push into oncology with phase 3 trials for pathfinder product Hernexeos and obrixtamig in hard-to-treat cancers. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Insilico and SK Bio forge $2.5bn AI neuroimmunity allianceNext: Lilly bets up to $800M for BioArctic’s brain delivery tech Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
